Sofiya Milman, Gil Atzmon, Jill Crandall and Nir Barzilai Pages 690 - 697 ( 8 )
A change in the lipoprotein profile is a metabolic hallmark of aging and has been the target for modern medical developments. Although pharmaceutical interventions aimed at lipid lowering substantially decrease the risk of cardiovascular disease, they have much less impact on mortality and longevity. Moreover, they have not affected death from other age-related diseases. In this review we focus on high density lipoprotein (HDL) cholesterol, the levels of which are either elevated or do not decrease as would be expected with aging in centenarians, and which are associated with lower prevalence of numerous age-related diseases; thereby, suggesting a potential HDL-mediated mechanism for extended survival. We also provide an update on the progress of identifying longevity-mediating lipid genes, describe approaches to discover longevity genes, and discuss possible limitations. Implicating lipid genes in exceptional longevity may lead to drug therapies that prevent several age-related diseases, with such efforts already on the way.
Aging, APOC3, CETP, genetics, HDL, longevity.
Institute for Aging Research, Department of Medicine, Division of Endocrinology, 1300, Morris Park Avenue, Bronx, NY 10461, Belfer Building, Suite 701, Albert Einstein College of Medicine.